Skip to content

Evaluation of potential serum biomarkers for individuals at risk of multiple sclerosis highlights SPP1.

Sep 2026 · Multiple Sclerosis and Related Disorders · Vol 115, pp. 107911 · 0 citations · 50 references
Medicine

TL;DR

Investigating whether alterations in six previously MS-associated biomarkers are detectable and associated with underlying genetic susceptibility in two independent sample collections suggest that several circulating proteins recently proposed as MS biomarkers are not robust tools to distinguish MS from healthy individuals.

Abstract

Circulating proteins have been widely investigated as potential biomarkers in multiple sclerosis (MS), yet findings across studies are often inconsistent, likely reflecting differences in disease stage, treatment exposure, and cohort composition. Studying individuals at elevated risk of MS prior to disease onset offers a unique opportunity to identify immune alterations that precede clinical disease while minimizing confounders. Here, we investigated whether alterations in six previously MS-associated biomarkers are detectable and associated with underlying genetic susceptibility in two independent sample collections consisting of persons with MS (pwMS), healthy participants, and asymptomatic first-degree relatives of pwMS from the Genes & Environment in MS (GEMS) study cohort. The panel, representing complementary axes of MS immunopathology, included granzyme A (GZMA), MER tyrosine kinase (MERTK), interleukin-2 receptor alpha (IL2RA), osteopontin (SPP1), CD30 (TNFRSF8), and chitinase-3-like protein 1 (CHI3L1). None of the proteins demonstrated associations with MS. A composite score constructed from externally derived effect estimates was associated with neither MS nor first-degree-relative status. Among asymptomatic first-degree relatives, higher genetic risk was associated with lower SPP1 levels for both the overall MS GRS and its non-MHC component, while TNFRSF8 was inversely associated with the non-MHC GRS in secondary analyses. Together, these findings suggest that several circulating proteins recently proposed as MS biomarkers are not robust tools to distinguish MS from healthy individuals. However, SPP1 levels are highlighted for further evaluation among at-risk individuals to determine whether circulating immune signatures can capture the earliest stages of MS in at-risk individuals.

View source

Similar papers

Open access Aug 2026

Distinct Multiomic Signatures of Environmental Exposure Drive Immune Dysregulation and Disease Activity in Early Multiple Sclerosis

While smoking cessation must likely be absolute to reverse pathogenic trafficking signals (such as GPR15 upregulation), the linear effect of BMI suggests that incremental weight loss confers proportional immunologic benefits, which strongly support the integration of lifestyle interventions as a core component of early...

Simon Falk, A. Schulte-Mecklenbeck, P. Ostkamp et al. · 0 citations
Open access Sep 2026

Epigenetic Insights in Pediatric Multiple Sclerosis

Background and Objectives Pediatric-onset multiple sclerosis (PedMS) provides a unique opportunity to investigate MS pathogenesis because of the short interval between environmental exposures and disease onset. This study aimed to identify differentially methylated regions (DMRs) that mediate the interplay between envi...

Andrea Corona, Martina Tosi, A. Zollo et al. · 0 citations
Open access Aug 2026

Chronic low-grade inflammation, genetic susceptibility, and the risk of multiple sclerosis: a prospective cohort study

The association of LGI with incident MS risk and MS-related brain structural measures in a large prospective cohort suggests that peripheral inflammation may serve as a potential marker for identifying individuals at elevated MS risk, warranting further investigation in interventional studies.

Yi-Zhou Cai, Yu-Jia Bao, Yong-Xuan Li et al. · 0 citations
Open access Jul 2026

Baseline plasma C1q and C3 as potential biomarkers for lecanemab efficacy and ARIA risk in early Alzheimer's disease

Lower baseline C3 was consistently associated with ARIA risk across sensitivity analyses and higher baseline C1q with smaller amyloid reduction at week 26, and this association persisted in international normalized ratio (INR)‐adjusted and simplified models.

Gihwan Byeon, Jung-Won Lee, Suhyung Kim et al. · 0 citations
Open access Aug 2026

Presymptomatic plasma biomarkers in autosomal dominant Alzheimer's disease: sequence and timing.

Multiple plasma proteins are elevated in presymptomatic and symptomatic ADAD mutation carriers relative to non-carriers, and combining biomarkers may help in staging presymptomatic AD and optimise clinical trial inclusion.

C. Belder, A. Heslegrave, O. Swann et al. · 1 citation
Open access Sep 2026

Large-Scale Plasma Proteomics Reveals Preclinical Biomarkers of Incident Severe Liver Disease.

This large-scale proteome-wide study not only reveals significant proteomic changes preceding SLD diagnosis but also establishes GDF15 as both a promising preclinical biomarker and opening new avenues for early intervention in at-risk individuals.

Shu-Zhen Zhao, Cheng-Nan Guo, Xin Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.